Nanorobotics in Healthcare

Nanorobotics in Healthcare

Nanorobots are devices that are used to treat or protect humans from pathogens. At nanoscale dimensions of one to one hundred nm, they are made to carry out a particular task or, in some cases, several tasks precisely.

The growing focus on regenerative medicine drives the growth of nanorobotics in healthcare. Regenerative medicine aims to harness the body's natural healing abilities and stimulate tissue regeneration to treat injuries and diseases effectively. Nanorobots play an essential role in this field by enabling precise and controlled interventions at the cellular and molecular levels. These nanoscale devices can be designed to deliver growth factors, therapeutic agents, and even stem cells to specific damaged areas, facilitating tissue repair and regeneration. For instance, in November 2022, MIT specialists developed another control system to definitively control how much a specific protein is delivered in mammalian cells utilizing a methodology in view of CRISPR proteins.

The Nanorobotics in Healthcare Market is expected to grow at a strong CAGR of 12.24% during the forecast period (2023-2030). The advancements in molecular nanorobots and nanomachines have ushered in a transformative era in healthcare driving the market for nanorobotics in healthcare. For instance, in February 2021, TESCAN announced the launch of a nanomanipulator for TEM sample lift-out and manipulation applications performed in TESCAN SEM and FIB-SEM instruments.

• Based on the methods of preparation, the market is segmented into biochip, nubots, biohybrids, bacteria-base, and virus-based. Amongst these, the biochip segment dominated the market in 2022. The nanorobotics in the healthcare market is expanding due to biochips that can carry out thousands of biological reactions in a few seconds. The market is expanding as a result of rising clinical research costs and an increasing number of cancer patients.
• By type, the market is segmented into pharmacyte, diagnosis and imaging, respirocyte, microbivores, and others. Among these, pharmacyte is expected to grow at a substantial CAGR during the forecasted period (2023-2030). They are designed to deliver drugs to specific cells or tissues in the body, which can be used to treat a range of diseases, including cancer, genetic disorders, and infectious diseases which will drive the growth of the market.
• On the basis of application, the market is segmented into nanorobotics in surgery, nanorobotics in gene therapy, nanorobotics in oncology, nanorobotics in dental, and others. The nanorobotics in the dental segment held a significant share of the market in 2022 due to the growing incidence of cancer patients. As per the Pan American Health Organization, in 2023, approximately 10 million cancer-related deaths and 20 million new cases worldwide. Adding to this, chemical biosensor-equipped nanorobots (nanosensors) are utilized for the early detection of tumor cells. The presence of cancerous cells in the body is detected by this nanosensor.
• For a better understanding of the market adoption of the nanorobotics in healthcare industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. North America dominated the nanorobotics in healthcare market in 2022 due to the launch of new products and rigorous R&D activities by companies in the nanorobotics market can drive the growth of the market by expanding product offerings, driving innovation, and increasing public awareness and understanding of the potential benefits of nanorobotics in medicine. Moreover, the increasing prevalence of cancer cases in America drives the growth of nanorobotics. In January 2023, the United States will see an estimated 609,820 deaths from cancer, or 1670 deaths per day, according to the American Cancer Society.
• Some of the major players operating in the market include Nanobiotix, Bruker, Novartis AG, Novavax, Nanoscribe GmbH & Co. KG, Siemens Healthcare GmbH, DNAe Group Holdings Ltd, Oxford Nanopore Technologies plc, Ocean NanoTech, Nanospectra Biosciences.